Status:
COMPLETED
Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU and COVID-19
Lead Sponsor:
University Hospital, Lille
Conditions:
Inflammatory Disease
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
This questionnaire is distributed via a mailing list (e-mail) of patients treated within the framework of the FHU for pathologies including chronic inflammatory bowel diseases or IBD (Crohn's disease ...
Eligibility Criteria
Inclusion
- patient followed for :
- Chronic inflammatory bowel disease or IBD (Crohn's disease and ulcerative colitis),
- Inflammatory rheumatism (rheumatoid arthritis and spondylitis)
- Multiple Sclerosis
- Asthma
- Psoriasis
- Atopic Dermatitis
- Systemic autoimmune diseases (scleroderma and lupus)
Exclusion
- Minor patient
- Patient cannot read or write
- Patient without computer equipment
- Patient with no internet access
- Patient not having filled in his e-mail in his file
- Patient does not wish to be contacted by email
Key Trial Info
Start Date :
July 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 27 2020
Estimated Enrollment :
921 Patients enrolled
Trial Details
Trial ID
NCT04513561
Start Date
July 21 2020
End Date
August 27 2020
Last Update
March 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez Chu Lille
Lille, France, 59037